Aduro BioTech (ADRO) Given a $10.00 Price Target by HC Wainwright Analysts

Aduro BioTech (NASDAQ:ADRO) has been assigned a $10.00 price objective by equities researchers at HC Wainwright in a report released on Tuesday, December 19th. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 39.86% from the stock’s previous close.

ADRO has been the subject of several other reports. Canaccord Genuity set a $30.00 target price on shares of Aduro BioTech and gave the company a “buy” rating in a report on Thursday, December 14th. William Blair reiterated an “outperform” rating on shares of Aduro BioTech in a report on Monday, October 2nd. BidaskClub lowered shares of Aduro BioTech from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. Finally, Oppenheimer lowered their target price on shares of Aduro BioTech from $15.00 to $13.00 and set an “outperform” rating for the company in a report on Wednesday, December 13th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $17.71.

Shares of Aduro BioTech (NASDAQ:ADRO) traded down $0.05 on Tuesday, reaching $7.15. 329,207 shares of the company’s stock traded hands, compared to its average volume of 522,463. Aduro BioTech has a twelve month low of $6.01 and a twelve month high of $14.05. The stock has a market capitalization of $548.86 and a price-to-earnings ratio of -5.26.

Aduro BioTech (NASDAQ:ADRO) last issued its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03). Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The company had revenue of $3.79 million during the quarter, compared to analysts’ expectations of $4.04 million. During the same quarter last year, the business earned ($0.54) earnings per share. The business’s quarterly revenue was up .0% on a year-over-year basis. equities research analysts forecast that Aduro BioTech will post -1.28 EPS for the current year.

In other Aduro BioTech news, insider Stephen T. Isaacs sold 7,949 shares of Aduro BioTech stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $7.95, for a total value of $63,194.55. Following the completion of the sale, the insider now owns 213,695 shares of the company’s stock, valued at approximately $1,698,875.25. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Jennifer Lew sold 6,600 shares of Aduro BioTech stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $9.46, for a total transaction of $62,436.00. Following the completion of the sale, the vice president now directly owns 68,938 shares of the company’s stock, valued at approximately $652,153.48. The disclosure for this sale can be found here. In the last ninety days, insiders sold 267,714 shares of company stock valued at $2,251,452. 6.60% of the stock is currently owned by insiders.

Several hedge funds have recently modified their holdings of ADRO. Harvard Management Co. Inc. bought a new stake in shares of Aduro BioTech during the 3rd quarter valued at $69,418,000. JPMorgan Chase & Co. grew its position in shares of Aduro BioTech by 283.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock valued at $4,244,000 after acquiring an additional 275,295 shares during the period. Nexthera Capital LP bought a new stake in shares of Aduro BioTech during the 2nd quarter valued at $1,767,000. Baillie Gifford & Co. grew its position in shares of Aduro BioTech by 45.8% during the 2nd quarter. Baillie Gifford & Co. now owns 422,700 shares of the biotechnology company’s stock valued at $4,819,000 after acquiring an additional 132,700 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Aduro BioTech by 5.4% during the 2nd quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock valued at $28,637,000 after acquiring an additional 129,079 shares during the period. 45.19% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/01/14/hc-wainwright-analysts-give-aduro-biotech-adro-a-10-00-price-target-updated-updated.html.

About Aduro BioTech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Analyst Recommendations for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply